. 2018 Jun 5;4(11):1589–1593. doi: 10.1001/jamaoncol.2018.2297

Table. Clonal Hematopoiesis in Solid Tumor Mutations With Treatment Implications Based on OncoKB Database.

Sex/Age at Blood Sampling, y	Gene	Amino Acid Change	VAF		Cancer Type	Highest OncoKB Level^a
Sex/Age at Blood Sampling, y	Gene	Amino Acid Change	Blood	Tumor	Cancer Type	Highest OncoKB Level^a
M/84	BRCA2	Q3156*	0.344	0.118	Melanoma	2B
M/74	IDH2	R140Q	0.405	0.082	Pancreatic	2B
F/72	IDH2	R140Q	0.298	0.063	NSCLC	2B
M/68	IDH2	R140Q	0.162	0.048	NSCLC	2B
M/76	IDH2	R140Q	0.270	0.039	NSCLC	2B
F/59	BRCA1	E1836Q	0.332	0.036	Endometrial	2B
F/74	NRAS	G12R	0.442	0.119	NSCLC	3B
F/80	NRAS	G12V	0.081	0.037	Uterine sarcoma	3B
F/83	IDH1	R132H	0.077	0.033	Melanoma	3B
F/70	IDH1	R132C	0.048	0.022	Melanoma	3B
M/43	PTEN	D24G	0.348	0.174	Colorectal	4
F/50	NF1	R2616*	0.237	0.095	Breast carcinoma	4
M/68	KRAS	G60D	0.297	0.094	Prostate	4
M/55	NF1	X1554_splice	0.105	0.049	Melanoma	4
M/79	NF1	F256Lfs*	0.141	0.043	Prostate	4
M/78	KRAS	A146P	0.132	0.035	Skin cancer, nonmelanoma	4
F/77	KRAS	G12R	0.087	0.041	Colorectal	R1

Abbreviations: FDA, US Food and Drug Administration; NSCLC, non–small cell lung cancer; VAF, variant allele fraction.

^{^a}

Level 2B indicates alterations that are standard-of-care biomarkers of response to an FDA-approved drug in another indication. Level 3B indicates compelling clinical evidence supporting the biomarker as being predictive of response to a drug in another indication. Level 4 indicates compelling biological evidence supporting the biomarker as being predictive of response to a drug. Level R1 indicates standard-of-care biomarker predictive of resistance to an FDA-approved drug in this indication.